Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06218303 · ClinicalTrials.gov registry record · Phase 1
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
A Phase 1 study of Ductal Carcinoma In Situ, sponsored by Finn, Olivera, PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06218303 is a Phase 1 study of Ductal Carcinoma In Situ that is actively recruiting participants, run by Finn, Olivera, PhD. The registered enrollment target is 50 participants, below the 254-participant average among 15 other Ductal Carcinoma In Situ trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06218303, a Phase 1 study of Ductal Carcinoma In Situ, is actively recruiting participants, sponsored by Finn, Olivera, PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Women with biopsy-proven ductal carcinoma in situ (DCIS) will be enrolled into two cohorts. One cohort will receive neoadjuvant therapy with an aromatase inhibitor or selective estrogen receptor modulator (SERM) for about 12 weeks prior to surgery at 12 weeks. The second cohort will receive neoadjuvant therapy with an aromatase inhibitor or selective estrogen receptor modulator and MUC1 vaccination (MUC1 peptide + Hiltonol®) pre-operatively at baseline, and weeks 2 and 10, followed by surgery at about 12 weeks. Patients in the vaccine cohort will be offered an optional boost vaccine 6 months after surgery.
Conditions Studied
Interventions
- BIOLOGICAL MUC1 Peptide Vaccine
- DRUG Hiltonol®
- DRUG Aromatase Inhibitor
- DRUG Selective estrogen receptor modulator (SERM)
Study Locations (1)
Pennsylvania
- UPMC Magee Womens Hospital - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-02-07 |
| Est. Completion | 2029-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06218303
The ClinicalTrials.gov registry entry for NCT06218303 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 254-participant average among 15 other Ductal Carcinoma In Situ trials with a reported enrollment target (80% lower). The listed sponsor is Finn, Olivera, PhD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ductal Carcinoma In Situ appearing as the primary indexed condition, and to 4 interventions - of which MUC1 Peptide Vaccine is the first listed.
NCT06218303 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06218303 about?
NCT06218303 is a clinical study titled "Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ". Women with biopsy-proven ductal carcinoma in situ (DCIS) will be enrolled into two cohorts. One cohort will receive neoadjuvant therapy with an aromatase inhibitor or selective estrogen receptor modulator (SERM) for about 12 weeks prior to surgery at 12 weeks. The second cohort will receive neoadjuv...
What is the current status of trial NCT06218303?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2024-02-07. Estimated completion is 2029-03-31.
What conditions does trial NCT06218303 study?
This clinical trial studies the following conditions: Ductal Carcinoma In Situ.
What interventions are being tested in trial NCT06218303?
The interventions under investigation include: MUC1 Peptide Vaccine (BIOLOGICAL), Hiltonol® (DRUG), Aromatase Inhibitor (DRUG), Selective estrogen receptor modulator (SERM) (DRUG).
Who is sponsoring clinical trial NCT06218303?
This trial is sponsored by Finn, Olivera, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06218303 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ductal Carcinoma In Situ
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
RECRUITING
-
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
RECRUITING · NA
-
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
RECRUITING · NA
-
Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions
RECRUITING · NA
-
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
RECRUITING · Phase 2
-
Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.